News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
Moderna's mRNA-4359 advances to Phase 2 in CPI-R/R melanoma patients. Promising data on tumor response rates and safety presented at ESMO Congress 2025 -
-
-
-